NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus...
NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus...
NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus Placebo Of 36.3% At Day 84 And 41.5% At Day 365
NewAmsterdam Pharma在2024年美國心臟協會科學會議上發佈了關於評估Obicetrapib在患有雜合子家族性高膽固醇血癥患者中的第三階段BROOKLYN臨床試驗的額外數據；在第84天與安慰劑相比，LDL-C的平均降低達到36.3%，在第365天達到了41.5%。
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –
– 在第84天與安慰劑相比，LDL-C的平均降低達到36.3%，在第365天達到41.5% –
– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –
– Lp(a)在第84天與安慰劑相比減少了45.9%，在第365天減少了54.3% –
– Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% –
– 總LDL-P在第180天與安慰劑相比減少了52.5%，小LDL-P減少了102.4% –
– Safety results comparable to placebo –
– 安全性結果與安慰劑相當 –
NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia ("HeFH"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The data were presented today in an oral late-breaker presentation at the American Heart Association (AHA) Scientific Sessions.
荷蘭納爾登和美國邁阿密，2024年11月18日（GLOBE NEWSWIRE）——NewAmsterdam Pharma Company N.V.（納斯達克：NAMS）是一家晚期臨床生物製藥公司，致力於開發針對具有心血管疾病（"CVD"）風險且低密度脂蛋白膽固醇（"LDL-C"）升高患者的口服非他汀類藥物，現有治療方案不能夠有效或耐受，今天宣佈了該公司第三階段BROOKLYN臨床試驗（NCT05425745）評估在儘管接受了最大耐受的降脂治療但LDL-C未得到有效控制的雜合子家族性高膽固醇血癥（"HeFH"）成人患者中使用obicetrapib的額外結果。今天在美國心臟協會（AHA）科學會議上進行了口頭晚期報告。
譯文內容由第三人軟體翻譯。